Inmolecule Nanotech, S.A.
MLINA | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- ES0105908000
- LEI:
- 959800F0D3TQYVTXW034
- Country:
- Spain
- Address:
- N/A
- Website:
- https://www.inmolecule.com
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Inmolecule Nanotech, S.A. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Inmolecule Nanotech, S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Inmolecule Nanotech, S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops targeted precision medicines for high-need cancers like leukemia, head & neck, and lung cancer.
United States of America
KURA
United States of America
KURA
Clinical-stage biotech developing protein therapies for rare diseases like Friedreich's ataxia.
United States of America
LRMR
United States of America
LRMR
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
United States of America
LEXX
Advancing a next-gen ADC platform to develop innovative medicines for unmet needs.
South Korea
141080
South Korea
141080
Global CRO providing full-service drug development support for biopharma companies.
Japan
2183
Japan
2183
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Sweden
LPGO
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM
Sweden
LIPUM
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
United States of America
LIXT